Trending: Investing in Bitcoin / 5 reasons to invest in Amazon / Investing in the Metaverse
Thursday, January 26, 2023
INVESTOR TIMES
  • Home
  • News
    Bets increase on a soft landing in the U.S

    Bets increase on a soft landing in the U.S

    69% of investors believe metaverse entertainment will change social lifestyles

    69% of investors believe metaverse entertainment will change social lifestyles

    European oil companies want to follow in Chevron’s footsteps to operate in Venezuela

    European oil companies want to follow in Chevron’s footsteps to operate in Venezuela

    Amgen buys Horizon Therapeutics for US$ 25 billion

    Amgen buys Horizon Therapeutics for US$ 25 billion

    Europe prepares law to make airlines that pollute more pay higher costs

    Europe prepares law to make airlines that pollute more pay higher costs

    Why are Asian investors selling their tech stocks?

    Why are Asian investors selling their tech stocks?

    Here’s what the economy and markets will look in 2023, according to JP Morgan

    Here’s what the economy and markets will look in 2023, according to JP Morgan

    Are technology stocks coming to the end of their reign?

    Are technology stocks coming to the end of their reign?

    Amazon fined millions for manipulating algorithms in its favor

    Amazon fined millions for manipulating algorithms in its favor

  • Markets
    Bets increase on a soft landing in the U.S

    Bets increase on a soft landing in the U.S

    What are CFDs and what are their advantages?

    Getting started with CFD trading

    Goldman Sachs lands with more strength at Santander and BBVA

    Goldman Sachs lands with more strength at Santander and BBVA

    With inflation in recession, what stocks should you consider?

    With inflation in recession, what stocks should you consider?

    Should payment for order flow be maintained in the stock market?

    Should payment for order flow be maintained in the stock market?

    Why are Asian investors selling their tech stocks?

    Why are Asian investors selling their tech stocks?

    Here’s what the economy and markets will look in 2023, according to JP Morgan

    Here’s what the economy and markets will look in 2023, according to JP Morgan

    Are technology stocks coming to the end of their reign?

    Are technology stocks coming to the end of their reign?

    Inflation is starting to ease but not enough

    Inflation is starting to ease but not enough

  • Investing
    Two biotech stocks that could explode soon

    Two biotech stocks that could explode soon

    Ideas for investing in the electric vehicle industry

    Ideas for investing in the electric vehicle industry

    Mercado Libre could be one of the best investments for the long term

    Mercado Libre could be one of the best investments for the long term

    Three cheap tech stocks for 2023

    Three cheap tech stocks for 2023

    Where to invest in 2023? These are the most likely trends

    Where to invest in 2023? These are the most likely trends

    Will Ford shares be profitable in 2023?

    Will Ford shares be profitable in 2023?

    Some interesting options for investing in leisure and travel companies

    Some interesting options for investing in leisure and travel companies

    Plug Power’s commitment to green hydrogen

    Plug Power’s commitment to green hydrogen

    Investing in Auto Trader: vehicle sales at a turning point

    Investing in Auto Trader: vehicle sales at a turning point

  • Technology
    Banning TikTok in the U.S. could benefit Meta

    Banning TikTok in the U.S. could benefit Meta

    Microsoft leads the ranking of the best-managed companies in 2022

    Microsoft leads the ranking of the best-managed companies in 2022

    Apple: consequences of the Foxconn conflict will continue until 2023

    Apple: consequences of the Foxconn conflict will continue until 2023

    5 must-have skills to get a job in 2023

    5 must-have skills to get a job in 2023

    UK changes strategy on Internet content control

    UK changes strategy on Internet content control

    EU organized a party in the metaverse and nobody attended

    EU organized a party in the metaverse and nobody attended

    The metaverse companies with the highest revenues in 2022

    The metaverse companies with the highest revenues in 2022

    Electric vehicles: China aims to boost its dominance

    Electric vehicles: China aims to boost its dominance

    Nintendo sells 10 million Switch in 3 days and its shares rise

    Nintendo sells 10 million Switch in 3 days and its shares rise

  • CryptocurrenciesTRENDING
    69% of investors believe metaverse entertainment will change social lifestyles

    69% of investors believe metaverse entertainment will change social lifestyles

    Bitcoin falls after Fed decision to raise interest rates by 0.50%

    Bitcoin falls after Fed decision to raise interest rates by 0.50%

    The future of cryptocurrencies, according to Larry Fink

    The future of cryptocurrencies, according to Larry Fink

    How Much Bitcoin Should You Buy: 5 Factors to Consider in 2023

    How Much Bitcoin Should You Buy: 5 Factors to Consider in 2023

    Between two extremes: what will the price of Bitcoin be in 2023?

    Between two extremes: what will the price of Bitcoin be in 2023?

    FTX crash spreads and affects BlockFi

    FTX crash spreads and affects BlockFi

    EU organized a party in the metaverse and nobody attended

    EU organized a party in the metaverse and nobody attended

    Why does The WSJ continue to question Tether’s financial health?

    Why does The WSJ continue to question Tether’s financial health?

    Brazilian Congress approves bill to regulate cryptocurrencies

    Brazilian Congress approves bill to regulate cryptocurrencies

S&P 500 (USA) 
4.060.43  44.21  1.10%  
NASDAQ Composite (USA) 
11.512.41  199.06  1.76%  
Dow Jones (USA) 
33.949.41  205.57  0.61%  
FTSE 100 (United Kingdom) 
7.761.11  16.24  0.21%  
EURO STOXX 50 (Europe) 
4.173,98  25,87  0,00%  
Nikkei 225 
27.409.42  46.67  0.17%  
VIX 
18.73  0.35  1.83%  
Bitcoin (USD) 
22.991.26  106.47  0.46%  
Ethereum (USD) 
1.598.04  13.41  0.83%  
  • Home
  • News
    Bets increase on a soft landing in the U.S

    Bets increase on a soft landing in the U.S

    69% of investors believe metaverse entertainment will change social lifestyles

    69% of investors believe metaverse entertainment will change social lifestyles

    European oil companies want to follow in Chevron’s footsteps to operate in Venezuela

    European oil companies want to follow in Chevron’s footsteps to operate in Venezuela

    Amgen buys Horizon Therapeutics for US$ 25 billion

    Amgen buys Horizon Therapeutics for US$ 25 billion

    Europe prepares law to make airlines that pollute more pay higher costs

    Europe prepares law to make airlines that pollute more pay higher costs

    Why are Asian investors selling their tech stocks?

    Why are Asian investors selling their tech stocks?

    Here’s what the economy and markets will look in 2023, according to JP Morgan

    Here’s what the economy and markets will look in 2023, according to JP Morgan

    Are technology stocks coming to the end of their reign?

    Are technology stocks coming to the end of their reign?

    Amazon fined millions for manipulating algorithms in its favor

    Amazon fined millions for manipulating algorithms in its favor

  • Markets
    Bets increase on a soft landing in the U.S

    Bets increase on a soft landing in the U.S

    What are CFDs and what are their advantages?

    Getting started with CFD trading

    Goldman Sachs lands with more strength at Santander and BBVA

    Goldman Sachs lands with more strength at Santander and BBVA

    With inflation in recession, what stocks should you consider?

    With inflation in recession, what stocks should you consider?

    Should payment for order flow be maintained in the stock market?

    Should payment for order flow be maintained in the stock market?

    Why are Asian investors selling their tech stocks?

    Why are Asian investors selling their tech stocks?

    Here’s what the economy and markets will look in 2023, according to JP Morgan

    Here’s what the economy and markets will look in 2023, according to JP Morgan

    Are technology stocks coming to the end of their reign?

    Are technology stocks coming to the end of their reign?

    Inflation is starting to ease but not enough

    Inflation is starting to ease but not enough

  • Investing
    Two biotech stocks that could explode soon

    Two biotech stocks that could explode soon

    Ideas for investing in the electric vehicle industry

    Ideas for investing in the electric vehicle industry

    Mercado Libre could be one of the best investments for the long term

    Mercado Libre could be one of the best investments for the long term

    Three cheap tech stocks for 2023

    Three cheap tech stocks for 2023

    Where to invest in 2023? These are the most likely trends

    Where to invest in 2023? These are the most likely trends

    Will Ford shares be profitable in 2023?

    Will Ford shares be profitable in 2023?

    Some interesting options for investing in leisure and travel companies

    Some interesting options for investing in leisure and travel companies

    Plug Power’s commitment to green hydrogen

    Plug Power’s commitment to green hydrogen

    Investing in Auto Trader: vehicle sales at a turning point

    Investing in Auto Trader: vehicle sales at a turning point

  • Technology
    Banning TikTok in the U.S. could benefit Meta

    Banning TikTok in the U.S. could benefit Meta

    Microsoft leads the ranking of the best-managed companies in 2022

    Microsoft leads the ranking of the best-managed companies in 2022

    Apple: consequences of the Foxconn conflict will continue until 2023

    Apple: consequences of the Foxconn conflict will continue until 2023

    5 must-have skills to get a job in 2023

    5 must-have skills to get a job in 2023

    UK changes strategy on Internet content control

    UK changes strategy on Internet content control

    EU organized a party in the metaverse and nobody attended

    EU organized a party in the metaverse and nobody attended

    The metaverse companies with the highest revenues in 2022

    The metaverse companies with the highest revenues in 2022

    Electric vehicles: China aims to boost its dominance

    Electric vehicles: China aims to boost its dominance

    Nintendo sells 10 million Switch in 3 days and its shares rise

    Nintendo sells 10 million Switch in 3 days and its shares rise

  • CryptocurrenciesTRENDING
    69% of investors believe metaverse entertainment will change social lifestyles

    69% of investors believe metaverse entertainment will change social lifestyles

    Bitcoin falls after Fed decision to raise interest rates by 0.50%

    Bitcoin falls after Fed decision to raise interest rates by 0.50%

    The future of cryptocurrencies, according to Larry Fink

    The future of cryptocurrencies, according to Larry Fink

    How Much Bitcoin Should You Buy: 5 Factors to Consider in 2023

    How Much Bitcoin Should You Buy: 5 Factors to Consider in 2023

    Between two extremes: what will the price of Bitcoin be in 2023?

    Between two extremes: what will the price of Bitcoin be in 2023?

    FTX crash spreads and affects BlockFi

    FTX crash spreads and affects BlockFi

    EU organized a party in the metaverse and nobody attended

    EU organized a party in the metaverse and nobody attended

    Why does The WSJ continue to question Tether’s financial health?

    Why does The WSJ continue to question Tether’s financial health?

    Brazilian Congress approves bill to regulate cryptocurrencies

    Brazilian Congress approves bill to regulate cryptocurrencies

INVESTOR TIMES
Home Investing

Two biotech stocks that could explode soon

Less than $10 can buy each share of these companies. Why are they special? Because the FDA may soon approve their drugs.

Alejandro Gil by Alejandro Gil
12/13/2022 - 16:31
in Investing
Reading Time: 4 mins read
Share on FacebookShare on TwitterShare on LinkedIn
  • Stocks of companies in the biotechnology sector are characterized by their attractiveness, regardless of the financial climate.
  • If these companies have key research on a drug that radically changes a health condition, they have a plus.
  • This paper presents two such companies that could generate significant returns if bought now.

In a recent article, we presented some investment options in technology companies that could make a difference. However, the sector is not without risk for many investors with low risk tolerance. If that is the case, two biotech stocks that could deliver significant returns with lower chances of failure are now presented.

The cardinal point here is that companies linked to the healthcare sector will always be of relevance. The latter is as true in times of bull markets as it is in times of recession. People need advances in medical science in any scenario and that is when technological developments in which some companies excel appear.

For investors, knowing those companies and what their jobs and potential are is one of the key tasks for success. In this paper we present two companies that are currently developing drugs that could be transcendental. Also, if they receive approval from the Food and Drug Administration (FDA), their shares could take a giant leap forward. The good news: both are under $10 per share.

Some clarification on biotech stocks

As stated earlier, biotech stocks are low-cost and there will always be demand for these companies’ products. However, there are “buts” that investors should consider before making any decisions. In this case, it should not be overlooked that the products of these companies do not resemble those of others in terms of timing.

“Successful investments in biopharma companies are not always short-range and the road is often fraught with setbacks.”

For example, for companies like Samsung, a defective cell phone released to the market is picked up again to tweak it. That scenario is negated for companies involved in the health area and the reasons are obvious. In that sense, the FDA will not license drugs that have not passed all phases of clinical trials.

The latter translates into time. In other words, investments in the sector are not for the impatient or for people with weak nerves. Pharmaceutical companies’ products often take years or even decades before advancing from one phase to the next, especially for pathologies that harm millions of people every year. Add to this the setbacks that some of these companies often face due to unfair competition or conspiracy theories.

Either way, the shares of biotech companies are a veritable roller coaster that is barely surpassed by some cryptocurrencies. Meanwhile, the late deliveries and negative quarterly results that companies always drag along are a headache for unprepared investors.

That said, it should be added that waiting and endurance provide rewards like no other. The returns offered by the shares of some companies in the sector can change completely with just one approval from U.S. regulators.

These are the two biotech stocks that could be hidden gems

Knowing the context of investing in companies in the sector, it should be noted that the risks are considerable. But a varied and well-ordered portfolio of pharmaceutical companies will always be, if I may say so, healthy. These are the two companies that could become the next source of returns for your investors:

  1. TG Therapeutics (TGTX).
  2. Acer Therapeutics (ACER)

There are three basic elements that determine that the shares of a company in the sector will enter an uptrend. These are positive clinical trial results, potential regulatory agency approval and the launch of a new drug to combat a pathology. If at least two of these catalysts come together, the chances of success are almost certain.

Even if some companies are in the midst of a long lead time for their products, one of these three elements would be enough to drive the stock price higher. That means those three catalysts have mechanics that are not subject to market conditions, which is good news for investors.

The latter translates into biotech stocks potentially starting a rally against the tide. The two companies cited for this paper received praise from analysts. The data for these two companies was taken from TipRanks and cross-checked with other portals such as Yahoo Finance.

1. TG Therapeutics

TG stands out among shares of biotechnology companies
Image: Finance.yahoo.com

This biopharmaceutical research company specializes in creating new treatments for B-cell diseases. These are serious autoimmune conditions. They are characterized by a loss of B-cell tolerance and inadequate production of certain antibodies. Among the most common manifestations of this condition are multiple sclerosis and rheumatoid arthritis.

The key element of TG that captivates analysts is that it has a huge pipeline of options for these diseases. Some of the likely drugs are in early stage clinical trials and one of them is on the frontier of FDA approval.

This is ublituximab, which is “a glycoengineered monoclonal antibody designed to target a ‘single epitope on CD20-expressing B cells,'” TipRanks says. This drug recently completed two Phase 3 trials (Ultimate I and II). Based on the results obtained, the company felt confident to apply for an FDA biologics license. By December 28, 2022, the company would meet the requirements for acceptance by the regulatory agency.

This drug is the company’s big news and would be preparing for a commercial launch in early 2023. If the drug is finally approved, the company’s shares would be at the top of the biotechnology sector in a few weeks.

Some analysts such as Ladenburg’s Matt Kaplan – consulted on the aforementioned portal – are extremely bullish. He believes that the company’s shares will reach $22 dollars from now until one year from now. This is a 168% growth considering that the current price is $8.56 dollars per share, according to Yahoo Finance.

Four other Wall Street analysts are fully betting on buying the stock, giving it a “strong buy” rating. The consensus places a price target of $19.75 per share.

2. Acer Therapeutics

ACER is another of the sector's strongest bets
Image: Finance.yahoo.com

The second of these companies is no slouch in terms of its projects and potential for share growth. Acer is focused on fighting serious metabolic diseases, particularly those conditions that due to their rarity do not have appropriate medical treatments. The company has three strong drug candidates. Among them, the most advanced is ACER-001.

This remedy is based on the treatment of inborn errors of metabolism, TipRanks explains. Among the diseases it neutralizes are urea cycle disorders, OTCs and maple syrup-smelling urine disease (MSUD). The latter is a rare condition in some infants and is caused by the body’s inability to break down some parts of proteins.

The FDA license application was resubmitted in July of this year and the cycle is expected to be completed by the end of January 2023. Although the application has already been rejected, the regulatory agency itself clarified that it was not a matter of problems with the drug, but of infrastructure and other protocols.

In any case, the reports of the aforementioned media say that within the company, optimism is exultant. This is evidenced by the fact that the CEO himself, Steven Lisi, has reportedly bought more than 819,836 shares of the company. Similarly, the firm’s president also purchased 409,836 shares at a cost of $500,000. Optimism is also expressed by Wall Street analysts.

Out of four analysts consulted by the portal, all of them are betting on a solid buy vote and none of them thinks that it would be a good option to sell or sell. Thus, the rating is “strong buy”. The price target for the stock is $9.67 per unit. At Monday’s close, the stock was trading at $2.9, up 37% in 24 hours. Nearly 500% would be the stock’s growth a year from now, according to analysts.

Thus, the shares of these biotech companies are emerging as two winning options.

This work is not investment advice. Its content is merely informative.

Tags: BiotechnologyFDAhealthsharesStock exchange

Related articles

Ideas for investing in the electric vehicle industry
Investing

Ideas for investing in the electric vehicle industry

by Pablo Petovel
— December 12, 2022
Mercado Libre could be one of the best investments for the long term
Investing

Mercado Libre could be one of the best investments for the long term

by Alejandro Gil
— December 12, 2022
Three cheap tech stocks for 2023
Investing

Three cheap tech stocks for 2023

by Alejandro Gil
— December 5, 2022
Where to invest in 2023? These are the most likely trends
Investing

Where to invest in 2023? These are the most likely trends

by Alejandro Gil
— November 29, 2022
Will Ford shares be profitable in 2023?
Investing

Will Ford shares be profitable in 2023?

by Alejandro Gil
— November 28, 2022

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Last published articles

Bets increase on a soft landing in the U.S
Markets

Bets increase on a soft landing in the U.S

by Alejandro Gil
— January 24, 2023
69% of investors believe metaverse entertainment will change social lifestyles

69% of investors believe metaverse entertainment will change social lifestyles

by Santiago Contreras
  January 24, 2023

What are CFDs and what are their advantages?

Getting started with CFD trading

by David Romero
  January 24, 2023

European oil companies want to follow in Chevron’s footsteps to operate in Venezuela

European oil companies want to follow in Chevron’s footsteps to operate in Venezuela

by Alejandro Gil
  December 17, 2022

Goldman Sachs lands with more strength at Santander and BBVA

Goldman Sachs lands with more strength at Santander and BBVA

by Pablo Petovel
  December 17, 2022

Facebook Twitter LinkedIn Telegram RSS

ABOUT INVESTOR TIMES

INVESTOR TIMES is an independent publication of economic, finance and investment content, owned and operated by Altas Ventures.

MORE ABOUT US

  • Our team
  • Work with us
  • Advertise on IT
  • Contact
  • Corporate information
  • Terms of Use
  • Cookies Policy
  • Privacy Policy

INTERNATIONAL EDITIONS

Investor Times in English

Investor Times en Français

Investor Times in Deutsch

Investor Times in Italiano

Investor Times em Português

Investor Times po Polsku

Investor Times на русском языке

El País Financiero (edición en Español)

© ATLAS VENTURES SLU, all rights reserved. Any information contained in INVESTOR TIMES is for educational and/or informational purposes only, it is not financial and/or investment advice. INVESTOR TIMES may obtain economic retribution by recommending services or products of third parties. INVESTOR TIMES does not accept, nor will it accept in the future, subsidies or funds from Governments, political parties or public institutions.

No Result
View All Result
  • Home
  • News
  • Markets
  • Investing
  • Cryptocurrencies
  • Technology

  •  EXCLUSIVE  3 Russian men are the real perpetrators behind Juicy Fields, says Glanse

     NEW  Compound Interest Calculator

     TRENDING 
    Investing in Bitcoin Investing in the Metaverse 5 reasons to invest in Amazon

© ATLAS VENTURES, all rights reserved.